Skip to Videos
  • Is the 340B program the next 'Too Big To Fail?' - Charity Care
    • 12/2/25

    Is the 340B program the next 'Too Big To Fail?' - Charity Care

    Congress created the 340B Drug Pricing Program to extend federal resources and improve patient care. The Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, also known as charity care. What’s particularly striking is that charity care continues to decline year after year.

  • Is the 340B program the next 'Too Big To Fail?' - Exec Comp (60s)
    • 10/21/25

    Is the 340B program the next 'Too Big To Fail?' - Exec Comp (60s)

    The 340B Drug Pricing Program has a dirty little secret: drug manufacturer rebates intended to help poor patients access healthcare services are being used to fund excessive compensation for hospital CEOs. This program was designed to help patients, not pad the pockets of healthcare executives.

  • Is the 340B program the next 'Too Big To Fail?' - Exec Comp (30s)
    • 10/21/25

    Is the 340B program the next 'Too Big To Fail?' - Exec Comp (30s)

    The 340B Drug Pricing Program has a dirty little secret: drug manufacturer rebates intended to help poor patients access healthcare services are being used to fund excessive compensation for hospital CEOs. This program was designed to help patients, not pad the pockets of healthcare executives.

  • Is the 340B program the next 'Too Big To Fail?' - Medical Debt (60s)
    • 8/18/25

    Is the 340B program the next 'Too Big To Fail?' - Medical Debt (60s)

    The 340B Drug Pricing Program was designed to help poor patients access healthcare services. Yet, despite this program growing to $66 billion, primarily benefiting hospitals, medical debt continues to be a crippling financial burden for many Americans, with most of the debt being owed to these 340B-eligible hospitals.

  • Is the 340B program the next 'Too Big To Fail?' - Medical Debt (30s)
    • 8/18/25

    Is the 340B program the next 'Too Big To Fail?' - Medical Debt (30s)

    The 340B Drug Pricing Program was designed to help poor patients access healthcare services. Yet, despite this program growing to $66 billion, primarily benefiting hospitals, medical debt continues to be a crippling financial burden for many Americans, with most of the debt being owed to these 340B-eligible hospitals.

  • Is the 340B program the next 'Too Big To Fail?'
    • 5/14/25

    Is the 340B program the next 'Too Big To Fail?'

    In 2008, we wondered if the financial bubble would burst as financial institutions deemed “too big to fail” teetered during a global economic crisis. Today, we watch the same thing happen to healthcare—particularly the 340B Drug Pricing Program.

  • PSA: Combat Counterfeit Drugs
    • 3/11/22

    PSA: Combat Counterfeit Drugs

    Brandon M. Macsata, CEO of the ADAP Advocacy Association and a long-term survivor living with HIV, shares some important steps patients can take to combat counterfeit drugs.

  • PSA: HIV COVID-19 #YourVaccineIsWaiting (Michelle Anderson)
    • 8/12/21

    PSA: HIV COVID-19 #YourVaccineIsWaiting (Michelle Anderson)

    #YourVaccineIsWaiting - Michelle Anderson, community activist and policy associate living with HIV, shares why she decided to get vaccinated against Covid-19.

  • PSA: HIV COVID-19 #YourVaccineIsWaiting (Tez Anderson)
    • 8/3/21

    PSA: HIV COVID-19 #YourVaccineIsWaiting (Tez Anderson)

    #YourVaccineIsWaiting - Tez Anderson, a long-term survivor living with HIV, shares why he decided to get vaccinated against Covid-19.